Kilitch Drugs Intrinsic Value
Kilitch Drugs (KILITCH) median intrinsic value is ₹262.03 from 9 valuation models (range ₹104–₹373), vs current price ₹183.06 — +43.1% upside (Trading Below Calculated Value), margin of safety 30.1%. Also explore KILITCH share price data to track price trends across different timeframes.
KILITCH Valuation Methods Summary — DCF, Graham Number & P/E
Kilitch Drugs intrinsic value across 9 models vs current price ₹183.06 — upside/downside and value range per method. For current market price and key ratios, visit Kilitch Drugs screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹373.12 | ₹298.50 - ₹447.74 | +103.8% | EPS: ₹16.96, Sector P/E: 22x |
| Book Value Method | asset | ₹251.25 | ₹226.12 - ₹276.38 | +37.3% | Book Value/Share: ₹125.62, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹366.12 | ₹329.51 - ₹402.73 | +100.0% | Revenue/Share: ₹225.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹366.12 | ₹329.51 - ₹402.73 | +100.0% | EBITDA: ₹92.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹104.44 | ₹83.55 - ₹125.33 | -42.9% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹108.54 | ₹97.69 - ₹119.39 | -40.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹262.03 | ₹235.83 - ₹288.23 | +43.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹366.12 | ₹329.51 - ₹402.73 | +100.0% | ROE: 29.9%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹218.95 | ₹197.06 - ₹240.84 | +19.6% | EPS: ₹16.96, BVPS: ₹125.62 |
KILITCH Intrinsic Value vs Market Price — All Valuation Models
Kilitch Drugs fair value range ₹104–₹373 vs current market price ₹183.06 across 9 valuation models. Browse KILITCH income statement for revenue, profit, balance sheet and cash flow data.
KILITCH Intrinsic Value Analysis — Undervalued or Overvalued?
Kilitch Drugs median intrinsic value ₹262.03, current price ₹183.06 — Trading Below Calculated Value by 43.1%, margin of safety 30.1%.
What is the intrinsic value of KILITCH?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Kilitch Drugs (KILITCH) is ₹262.03 (median value). With the current market price of ₹183.06, this represents a +43.1% variance from our estimated fair value.
The valuation range spans from ₹104.44 to ₹373.12, indicating ₹104.44 - ₹373.12.
Is KILITCH undervalued or overvalued?
Based on our multi-method analysis, Kilitch Drugs (KILITCH) appears to be trading below calculated value by approximately 43.1%.
KILITCH Financial Health — Key Ratios vs Industry Benchmarks
Kilitch Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 6.21 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 29.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.15x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
KILITCH Cash Flow Quality — Operating & Free Cash Flow
Kilitch Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹18 Cr | ₹-2 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹-2 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹6 Cr | ₹-2 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹46 Cr | ₹27 Cr | Positive Free Cash Flow | 8/10 |